Michael Burkes Brophy Sells 478 Shares of Natera (NASDAQ:NTRA) Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 478 shares of the stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $274.22, for a total value of $131,077.16. Following the completion of the sale, the chief financial officer owned 51,637 shares of the company’s stock, valued at $14,159,898.14. The trade was a 0.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, August 3rd, Michael Burkes Brophy sold 317 shares of Natera stock. The stock was sold at an average price of $267.99, for a total value of $84,952.83.
• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The shares were sold at an average price of $249.38, for a total value of $464,594.94.
• On Tuesday, July 28th, Michael Burkes Brophy sold 2,419 shares of Natera stock. The shares were sold at an average price of $253.96, for a total value of $614,329.24.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The stock was sold at an average price of $260.49, for a total value of $203,703.18.

Natera Trading Down 3.4%

Shares of NASDAQ NTRA opened at $265.38 on Friday. Natera, Inc. has a one year low of $136.21 and a one year high of $288.04. The firm has a market capitalization of $38.01 billion, a PE ratio of -162.81 and a beta of 1.51. The business has a 50-day moving average price of $252.06 and a two-hundred day moving average price of $223.09.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The company had revenue of $752.75 million for the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.The business’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.74) EPS. Research analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Trading of Natera

Several large investors have recently added to or reduced their stakes in the business. Robinhood Asset Management LLC bought a new position in shares of Natera in the fourth quarter valued at approximately $12,981,000. UBS Group AG lifted its stake in shares of Natera by 19.4% in the fourth quarter. UBS Group AG now owns 438,857 shares of the medical research company’s stock worth $100,538,000 after buying an additional 71,355 shares during the last quarter. ABN Amro Investment Solutions boosted its holdings in shares of Natera by 44.6% during the 1st quarter. ABN Amro Investment Solutions now owns 9,346 shares of the medical research company’s stock worth $1,869,000 after buying an additional 2,883 shares during the period. Fifth Third Bancorp boosted its holdings in shares of Natera by 3,373.1% during the 1st quarter. Fifth Third Bancorp now owns 11,253 shares of the medical research company’s stock worth $2,251,000 after buying an additional 10,929 shares during the period. Finally, Teacher Retirement System of Texas grew its stake in Natera by 286.8% in the 4th quarter. Teacher Retirement System of Texas now owns 65,717 shares of the medical research company’s stock valued at $15,055,000 after buying an additional 48,728 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera reported second-quarter revenue of $752.8 million, up 37.7% year over year and well above analysts’ $661.2 million estimate. Its adjusted loss of $0.47 per share was also slightly better than the $0.49 consensus and improved from a $0.74 loss a year earlier. Gross margin increased to 64.5% from 63.4%. Natera Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.9 billion, ahead of the roughly $2.8 billion analyst consensus. The outlook reinforces expectations for continued demand across Natera’s reproductive health, oncology, and transplant testing businesses.
• Positive Sentiment: Natera submitted its Signatera molecular residual disease test to Japan’s PMDA for approval as a companion diagnostic in muscle-invasive bladder cancer. Regulatory approval could expand Signatera’s international addressable market and create another source of oncology revenue. Natera Submits Signatera to Japan’s PMDA
• Neutral Sentiment: CEO Steven Leonard Chapman, CFO Michael Burkes Brophy, and other executives sold shares totaling about $2.0 million. The transactions were made under pre-arranged Rule 10b5-1 plans to cover tax withholding from vested equity awards, and the executives retained substantial holdings, limiting their value as a negative confidence signal.
• Negative Sentiment: Natera remains unprofitable, reporting a negative net margin and return on equity. Although the quarterly loss narrowed year over year, investors may be focused on the company’s path to sustained earnings, particularly after the stock’s sharp rise and proximity to its 52-week high.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on NTRA shares. UBS Group set a $260.00 price objective on shares of Natera in a research note on Wednesday, June 24th. Sanford C. Bernstein began coverage on shares of Natera in a research note on Friday, June 26th. They set an “outperform” rating and a $310.00 target price for the company. Guggenheim boosted their price target on shares of Natera from $270.00 to $290.00 and gave the company a “buy” rating in a report on Monday, June 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Natera in a research note on Friday, July 17th. Finally, Wolfe Research initiated coverage on Natera in a report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $267.83.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.